Edesa Biotech Inc (EDSA) — Cash Flow-to-Debt Ratio
Edesa Biotech Inc (EDSA) has a Cash Flow-to-Debt Ratio of -0.78x as of June 2026, meaning its operating cash flow of $-3.05 Million could theoretically repay -1% of its total liabilities ($3.91 Million) in one year. See financial agility of Edesa Biotech Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Edesa Biotech Inc Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Edesa Biotech Inc across 16 annual periods. For the full cash flow conversion analysis, see Edesa Biotech Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Edesa Biotech Inc (2010–2025)
Year-by-year debt coverage analysis for Edesa Biotech Inc. Check EDSA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.79x | $-7.32 Million | $1.08 Million | ▼ -154.5% |
| 2024 | -2.67x | $-4.89 Million | $1.83 Million | ▲ +26.0% |
| 2023 | -3.60x | $-6.64 Million | $1.84 Million | ▲ +35.9% |
| 2022 | -5.62x | $-12.28 Million | $2.18 Million | ▲ +37.2% |
| 2021 | -8.95x | $-13.66 Million | $1.53 Million | ▼ -197.0% |
| 2020 | -3.01x | $-4.99 Million | $1.65 Million | ▲ +71.3% |
| 2019 | -10.50x | $-4.85 Million | $461.63K | ▼ -12.2% |
| 2018 | -9.35x | $-4.62 Million | $493.38K | ▲ +36.1% |
| 2017 | -14.64x | $-4.70 Million | $320.95K | ▼ -102.7% |
| 2016 | -7.22x | $-4.51 Million | $623.64K | ▼ -289.8% |
| 2015 | -1.85x | $-4.41 Million | $2.38 Million | ▼ -194.2% |
| 2014 | -0.63x | $-4.27 Million | $6.77 Million | ▼ -151.0% |
| 2013 | -0.25x | $-2.92 Million | $11.65 Million | ▲ +95.6% |
| 2012 | -5.70x | $-3.95 Million | $692.27K | ▲ +65.3% |
| 2011 | -16.44x | $-2.62 Million | $159.14K | ▼ -844.5% |
| 2010 | -1.74x | $-732.23K | $420.61K | — |